Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 4/20 | 0.59 |
| ▸ | FPR2 | P25090 | 4/20 | 0.59 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 3/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 3/20 | 0.42 |
| ▸ | FNTB | P49356 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL9903983 | 0.83 | FPR1 (0.61) | FPR1FPR2MMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL39528 | 0.83 | FPR1 (0.61) | FPR1FPR2MMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL7127847 | 0.83 | FPR1 (0.61) | FPR1FPR2MMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL39529 | 0.83 | FPR1 (0.61) | FPR1FPR2MMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL4592799 | 0.83 | FPR1 (0.61) | FPR1FPR2MMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL17202476 | 0.83 | FPR1 (0.61) | FPR1FPR2MMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL4969844 | 0.83 | FPR1 (0.61) | FPR1FPR2MMP2 | |
| SCHEMBL9446555 | 0.83 | FPR1 (0.63) | FPR1FPR2CTSBMMP2MMP1 | |
| SCHEMBL9446563 | 0.83 | FPR1 (0.63) | FPR1FPR2CTSBMMP2MMP1 | |
| SCHEMBL27066372 | 0.82 | FPR1 (0.60) | FPR1FPR2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-11-02 | — | — | US | disclosed |
| EP-3225248-B1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11542310-B2 | Modified bovine G-CSF polypeptides and their uses | AMBRX, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220152155-A1 | FORMULATIONS FOR BOVINE GRANULOCYTE COLONY STIMULATING FACTOR AND VARIANTS THEREOF | ELANCO US INC (US) | 2022-05-19 | — | — | US | disclosed |
| US-11273202-B2 | Formulations for bovine granulocyte colony stimulating factor and variants thereof | ELANCO US INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20190071482-A1 | Modified Bovine G-CSF Polypeptides And Their Uses | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2019-03-07 | — | — | US | disclosed |
| US-10138283-B2 | Modified bovine G-CSF polypeptides and their uses | AMBRX, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| EP-2318029-B1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3225248-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | Ambrx, Inc. (US) | 2017-10-04 | — | — | EP | disclosed |
| EP-2618830-B1 | FORMULATIONS FOR BOVINE GRANULOCYTE COLONY STIMULATING FACTOR AND VARIANTS THEREOF | LILLY CO ELI (US) | 2015-04-15 | — | — | EP | disclosed |
| US-20120082641-A1 | FORMULATIONS FOR BOVINE GRANULOCYTE COLONY STIMULATING FACTOR AND VARIANTS THEREOF | ELI LILLY AND COMPANY (US) | 2012-04-05 | — | — | US | disclosed |
| WO-2012040421-A1 | FORMULATIONS FOR BOVINE GRANULOCYTE COLONY STIMULATING FACTOR AND VARIANTS THEREOF | ELI LILLY AND COMPANY (US) | 2012-03-29 | — | — | WO | disclosed |
| EP-2318029-A2 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | Ambrx, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20100035812-A1 | Modified Bovine G-CSF Polypeptides And Their Uses | AMBRX, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2010011735-A2 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-0719860-B1 | Process for isolating and purifying G-CSF | AMGEN INC (US) | 2009-12-16 | — | — | EP | disclosed |
| US-5849883-A | Method for purifying granulocyte colony stimulating factor | AMGEN INC. (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0719860-A1 | Compositions and method for treating or preventing infections in animals | AMGEN INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0347041-A2 | Compositions and method for treating or preventing infections in animals | AMGEN INC. (US) | 1989-12-20 | — | — | EP | disclosed |
| WO-1989010932-A1 | COMPOSITIONS AND METHOD FOR TREATING OR PREVENTING INFECTIONS IN ANIMALS | AMGEN INC. (US) | 1989-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035812-A1 | Modified Bovine G-CSF Polypeptides And Their Uses | CSF3R, GMFG, HDGF | FPR1 207/4885FPR2 153/4885CTSB 236/4885 |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | CSF3R, GMFG, HDGF | FPR1 207/4885FPR2 153/4885CTSB 236/4885 |
| US-10138283-B2 | Modified bovine G-CSF polypeptides and their uses | CSF3R, GMFG, HDGF | FPR1 207/4885FPR2 153/4885CTSB 236/4885 |
| US-20190071482-A1 | Modified Bovine G-CSF Polypeptides And Their Uses | CSF3R, GMFG, HDGF | FPR1 207/4885FPR2 153/4885CTSB 236/4885 |
| US-11542310-B2 | Modified bovine G-CSF polypeptides and their uses | CSF3R, GMFG, HDGF | FPR1 207/4885FPR2 153/4885CTSB 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.